I Can C Clearly Now, the End Is Near

Eileen Laurel Yoon^{1

2}, Dae Won Jun^{3

4}

Affiliations

¹ Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea.
² Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Republic of Korea.
³ Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Republic of Korea. noshin@hanyang.ac.kr.
⁴ Department of Internal Medicine, Hanyang University College of Medicine, 222-1, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea. noshin@hanyang.ac.kr.

Editorial

Eileen Laurel Yoon et al. Dig Dis Sci. 2025 Jan.

. 2025 Jan;70(1):26-28.

doi: 10.1007/s10620-024-08754-6. Epub 2024 Dec 2.

Eileen Laurel Yoon^{1

2}, Dae Won Jun^{3

4}

¹ Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea.
² Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Republic of Korea.
³ Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Republic of Korea. noshin@hanyang.ac.kr.
⁴ Department of Internal Medicine, Hanyang University College of Medicine, 222-1, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea. noshin@hanyang.ac.kr.

No abstract available

Keywords: Decompensated cirrhosis; Direct-acting antiviral drugs; Hepatitis C; Hepatitis C genotypes; Hepatocellular carcinoma.

Conflict of interest statement

Declarations. Competing interest: The authors declare no competing interests.

1. Wong YJ, Tran S, Huang CF et al. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatol Int. 2023;17:1150–1161. - DOI - PubMed
1. An J, Park DA, Ko MJ et al. Direct-acting antivirals for HCV treatment in decompensated liver cirrhosis patients: a systematic review and meta-analysis. J Pers Med. 2022;12:1517. - DOI - PubMed - PMC
1. Chon YE, Jo A, Yoon EL et al. The incidence and care cascade of the hepatitis C virus in Korea. Gut Liver. 2023;17:926–932. - DOI - PubMed - PMC
1. Lee J, Ahn SB, Yim SY et al. Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (>/=65 years old): a systematic review and meta-analysis. J Viral Hepat. 2022;29:496–517. - DOI - PubMed
1. Sohn W, Park SY, Lee TH et al. Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study. EClinMed 2024;73:102671.